Core Laboratories Inc. (CLB)
| Market Cap | 447.69M -39.7% |
| Revenue (ttm) | 516.74M -0.1% |
| Net Income | 15.56M -51.6% |
| EPS | 0.34 -50.3% |
| Shares Out | 45.82M |
| PE Ratio | 28.90 |
| Forward PE | 14.16 |
| Dividend | $0.04 (0.41%) |
| Ex-Dividend Date | Nov 9, 2026 |
| Volume | 523,569 |
| Open | 10.17 |
| Previous Close | 10.19 |
| Day's Range | 9.67 - 10.27 |
| 52-Week Range | 9.13 - 20.36 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 15.00 (+53.53%) |
| Earnings Date | Oct 28, 2026 |
About CLB
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize pr... [Read more]
Financial Performance
In 2025, Core Laboratories's revenue was $526.52 million, an increase of 0.51% compared to the previous year's $523.85 million. Earnings were $29.67 million, a decrease of -5.51%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CLB stock is "Buy." The 12-month stock price target is $15.0, which is an increase of 53.53% from the latest price.
News
Core Laboratories Earnings Call Transcript: Q3 2026
Q3 revenue and adjusted earnings improved sequentially, but geopolitical disruption continued to pressure services. Q4 revenue is expected to be broadly flat, while management sees potential for a broader global activity and spending recovery in 2027.
Core Laboratories Earnings release: Q3 2026
Core Laboratories released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Core Laboratories Quarterly report: Q3 2026
Core Laboratories has published its Q3 2026 quarterly earnings report on October 29, 2026.
Core Laboratories reports Q3 adjusted EPS 16c, consensus 16c
Reports Q3 revenue $132.1M, consensus $132.14M. Core’s CEO, Larry Bruno, stated, “Our third quarter results delivered sequential revenue growth across both of our operating segments. International rev...
Core Laboratories sees Q4 revenue ‘relatively flat sequentially’
For the fourth quarter of 2026, Core Lab expects revenue to remain relatively flat sequentially, reflecting continued disruptions in the Middle East. Early in the fourth quarter, attacks affected clie...
CORE LAB REPORTS THIRD QUARTER 2026 RESULTS:
REVENUE OF $ 132.1 MILLION, UP 6% SEQUENTIALLY AND DOWN 2% YEAR-OVER-YEAR OPERATING INCOME OF $ 12.1 MILLION; EX-ITEMS, $12.6 MILLION, UP 35% SEQUENTIALLY AND DOWN 24% YEAR-OVER-YEAR GAAP EARNINGS PER...
CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON, Oct. 1, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its third quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
Core Laboratories upgraded to Buy from Hold at Johnson Rice
Johnson Rice upgraded Core Laboratories (CLB) to Buy from Hold with an unchanged price target of $21.
Core Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 saw sequential revenue and margin growth despite geopolitical disruptions, with Production Enhancement outperforming and Reservoir Description impacted by Middle East and Russia/Ukraine conflicts. Guidance projects further sequential growth in Q3, driven by international markets and continued technology adoption.
Core Laboratories Earnings release: Q2 2026
Core Laboratories released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Core Laboratories Quarterly report: Q2 2026
Core Laboratories has published its Q2 2026 quarterly earnings report on July 30, 2026.
Core Laboratories reports Q2 EPS ex-items 11c, consensus 9c
Reports Q2 revenue $124.6M vs. $130.16M last year. CEO Larry Bruno, stated, “Our Q2 results displayed sequential improvement in revenue, operating income and earnings per share despite continued geopo...
Core Laboratories sees Q3 EPS 12c-20c, consensus 16c
Sees Q3 revenue $128.5M-$135.5M, consensus $131.33M.
CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR GAAP EARNINGS PER S...
Core Laboratories price target lowered to $11 from $12 at BofA
BofA lowered the firm’s price target on Core Laboratories (CLB) to $11 from $12 and keeps an Underperform rating on the shares. The firm updated estimates and targets as part…
CORE LABORATORIES ANNOUNCES TIMING OF SECOND QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON, June 30, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
Mobility Global to replace Core Laboratories in S&P 600 at open on 7/2
S&P Global (SPGI) is spinning off Mobility Global (MBGL) in a transaction expected to be completed July 1. Core Laboratories (CLB) is no longer representative of the small-cap market space.
Core Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 results were impacted by Middle East conflict, severe weather, and global supply disruptions, leading to lower revenue and margins. Despite these headwinds, the company maintained shareholder returns and expects modest sequential improvement, with long-term demand supported by global energy trends.
Core Laboratories Earnings release: Q1 2026
Core Laboratories released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Core Laboratories Quarterly report: Q1 2026
Core Laboratories has published its Q1 2026 quarterly earnings report on April 30, 2026.
Core Laboratories reports Q1 EPS 6c, consensus 11c
Reports Q1 revenue $121.8M, consensus $124.9M. Core’s CEO, Larry Bruno, stated, “First and foremost, our thoughts remain with our employees and their families across our Middle East operations during ...
Core Laboratories sees Q2 EPS 6c-12c, two estimates 14c
Sees Q2 revenue $123M-$131M, two estimates $127.9M
CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR OPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEAR GAAP LOSS PER SHARE OF $...
Core Laboratories Proxy statement: Proxy filing
Core Laboratories filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Core Laboratories Proxy statement: Proxy filing
Core Laboratories filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.